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Abstract
Aims An increasing proportion of patients with heart failure with reduced ejection fraction (HFrEF) have co‐morbidities. The
effect of these co‐morbidities on modes of death and the effect of disease‐modifying agents in multi‐morbid patients is
unknown.
Methods and results We performed a prospective cohort study of ambulatory patients with HFrEF to assess predictors of
outcomes. We identified four key co‐morbidities—ischaemic aetiology of heart failure, diabetes mellitus, chronic obstructive
pulmonary disease (COPD), and chronic kidney disease (CKD)—that were highly prevalent and associated with an increased
risk of all‐cause mortality. We used these data to explore modes of death and the utilization of disease‐modifying agents in
patients with and without these co‐morbidities. The cohort included 1789 consecutively recruited patients who had an aver-
age age of 69.6 ± 12.5 years, and 1307 (73%) were male. Ischaemic aetiology of heart failure was the most common co‐
morbidity, occurring in 1061 (59%) patients; 503 (28%) patients had diabetes mellitus, 283 (16%) had COPD, and 140 (8%)
had CKD stage IV/V. During mean follow‐up of 3.8 ± 1.6 years, 737 (41.5%) patients died, classified as progressive heart failure
(n ¼ 227, 32%), sudden (n ¼ 112, 16%), and non‐cardiovascular deaths (n ¼ 314, 44%). Multi‐morbid patients were older
(P < 0.001), more likely to be male (P < 0.001), and had higher New York Heart Association class (P < 0.001), despite having
higher left ventricular (LV) ejection fraction (P ¼ 0.001) and lower LV end‐diastolic diameter (P ¼ 0.001). Multi‐morbid pa-
tients were prescribed lower doses of disease‐modifying agents, especially patients with COPD who received lower doses of
beta‐adrenoceptor antagonists (2.7 ± 3.0 vs. 4.1 ± 3.4 mg, P < 0.001) and were less likely to be implanted with internal
cardioverter defibrillators (7% vs. 13%, P < 0.001). In multivariate analysis, COPD and diabetes mellitus conferred a >2.5‐fold
and 1.5‐fold increased risk of sudden death, whilst higher doses of beta‐adrenoceptor antagonists were protective (hazard ra-
tio per milligram 0.92, 95% confidence interval 0.86–0.98, P ¼ 0.009). Each milligram of bisoprolol‐equivalent beta‐
adrenoceptor antagonist was associated with 9% (P ¼ 0.001) and 11% (P ¼ 0.023) reduction of sudden deaths in patients with
<2 and ≥2 co‐morbidities, respectively.
Conclusions Higher doses of beta‐adrenoceptor antagonist are associated with greater protection from sudden death, most
evident in multi‐morbid patients. Patients with COPD who appear to be at the highest risk of sudden death are prescribed the
lowest doses and less likely to be implanted with implantable cardioverter defibrillators, which might represent a missed op-
portunity to optimize safe and proven therapies for these patients.
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Introduction
Background
The prevalence of chronic heart failure continues to rise, at
least in part owing to the widespread implementation of
disease‐modifying pharmacological therapies.1–3 Use of these
therapies has been accompanied by changes in the distribu-
tion of modes of death, particularly the relative contribution
of sudden death.4,5 Nevertheless, sudden death remains an
important contributor to potentially preventable mortality
in patients with heart failure with reduced ejection fraction
(HFrEF),6 with those with previous myocardial infarction, se-
vere left ventricular (LV) systolic dysfunction, prior ventricular
tachyarrhythmia, and co‐existent diabetes mellitus being at
the greatest risk.7–9
Additional contemporary epidemiologic changes include an
increasingly older population of patients with HFrEF and pro-
portion with co‐morbidities.10 Not only do co‐morbidities
contribute to disability, impairment of quality of life, and
poor outcomes,10 but they also complicate management
strategies and result in more frequent and increased duration
of hospitalizations.11–13 It is not known whether multi‐morbid
patients achieve doses of disease‐modifying agents, including
angiotensin‐converting enzyme‐inhibitors (ACEi) and
beta‐adrenoceptor antagonists achieved in clinical trials. Fur-
thermore, the effect of these medications in terms of reduc-
ing cardiovascular deaths in multi‐morbid patients is not
known.
The aims of this analysis were therefore, firstly, to report
the real‐world provision of disease‐modifying agents in a
cohort of patients with HFrEF attending specialist heart
failure clinics in the UK and secondly, to explore the
impact of multi‐morbidity on modes of death in HFrEF,
specifically whether co‐morbidities alter the relative risk of
sudden death. Finally, we aimed to determine whether
multi‐morbidity altered the effects of disease‐modifying
agents in preventing sudden death.
Methods
Study design
As described previously,14–16 this was a prospective cohort
study in unselected, ambulatory patients with HFrEF attend-
ing specialist cardiology clinics, with the a priori aim of de-
scribing contributors to outcome.
Participants
Between June 2006 and December 2014, consecutive
patients attending specialist cardiology clinics in four UK
hospitals were approached to participate. Inclusion required
patients to have stable signs and symptoms of chronic heart
failure for at least 3 months, age ≥ 18 years, and LV ejection
fraction (LVEF) ≤ 45% on transthoracic echocardiogram,
based upon guidelines for diagnostic and therapeutic criteria
in place at the time.17,18
Variables and data sources
At the time of study recruitment, patient demographics,
aetiology of LV impairment, past medical history, and
functional capacity according to the New York Heart Associa-
tion (NYHA) classification were collected. A venous blood
sample was taken at enrolment and tested for serum
haemoglobin, estimated glomerular filtration rate to stage
chronic kidney disease (CKD) and serum albumin. We per-
formed two‐dimensional echocardiography and measured
LV end‐diastolic diameter (LVEDd), LVEF by Simpson’s biplane
method, pulmonary artery systolic pressure, and the
presence of regional wall motion abnormality determined
by qualitative method according to the American Society of
Echocardiography recommendations at the time.19 Prescrip-
tion of ACEi, beta‐adrenoceptor antagonist, loop diuretic,
and mineralocorticoid receptor antagonist (MRA) were
recorded. For the purpose of analysis, doses of ACEi,
beta‐adrenoceptor antagonist, and loop diuretic are
expressed as equivalent doses, relative to the maximum li-
censed dosages of ramipril, bisoprolol, and furosemide as
previously described.20 Receipt of implantable cardioverter
defibrillator (ICD) or cardiac resynchronization therapy (CRT)
was assessed during the 6 month period after study
recruitment.
Assessment of outcomes
All patients were registered with the UK Office of Population
Censuses and Surveys, which provided details of the time of
death, with final censorship occurring in November 2018.
The primary outcomes of the current analysis were modes
of death in patients with and without major co‐morbidities.
Secondly, we examined the association between doses of
medication, provision of device therapy, and all‐cause mortal-
ity and mode of death.
Definitions
We identified four key co‐morbidities: ischaemic aetiology
of heart failure, diabetes mellitus, chronic obstructive pulmo-
nary disease (COPD), and CKD stage IV/V, which were highly
prevalent in the population and associated with an increased
risk of all‐cause mortality (Figure S1). We then used
these data to modes of death, which were classified as
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cardiovascular (including stroke) or non‐cardiovascular. Car-
diovascular deaths were further divided into progressive
heart failure or sudden deaths. Death due to progressive
heart failure was a death occurring during decompensation
or in patients with refractory symptoms. Sudden deaths were
any death, witnessed or unwitnessed, occurring within 1 h of
change in symptoms, or occurring during sleep or whilst the
patient was unobserved.21 Aetiology of LV impairment was
classified as either due to ischaemic heart disease when there
was previous myocardial infarction, coronary artery bypass
grafting, coronary stenting at index presentation, evidence
of inducible ischaemia on non‐invasive imaging or scar sug-
gesting infarction on cardiac magnetic resonance imaging,
or non‐ischaemic cardiomyopathy.
Statistics
All statistical analyses were performed using IBM SPSS Statis-
tics version 26 (IBM Corporation, Armonk, NY). After normal-
ity of distribution was demonstrated, continuous variables
are expressed as mean ± standard deviation. Discrete vari-
ables are presented as number and percentages in parenthe-
ses. Groups were compared using χ2 for categorical variables
and by Student’s t‐test or by one‐way analysis of variance for
continuous variables, as appropriate. Kaplan–Meier curves
were used to plot survival and compared with log‐rank test.
Age–sex‐adjusted and multivariate analyses used Cox propor-
tional hazards regression. In all analyses, statistical signifi-
cance was defined as P < 0.05.
Ethical considerations
Ethical approval was given by the Leeds West Research Ethics
Committee (07/Q1205/17) and conducted in accordance with
the principles outlined in the Declaration of Helsinki. All pa-
tients gave informed written consent for inclusion and
long‐term electronic follow‐up.
Results
Patients
During the study period, a total of 1802 patients with HFrEF
were recruited. Of these, five had missing medication doses
and eight were missing data on major co‐morbidities. The fi-
nal dataset for this analysis consisted on 1789 patients with
an average age of 69.6 ± 12.5 years, of whom 1307 (73%)
were male. A total of 472 (26%), 763 (43%), 446 (25%), and
108 (6%) had 0, 1, 2, or ≥3major co‐morbidities, respectively.
Ischaemic aetiology of heart failure was the most common
co‐morbidity, occurring in 1061 (59%) patients; 503 (28%)
patients had diabetes mellitus, 283 (16%) had COPD, and
140 (8%) had CKD stage IV/V (Table 1).
Descriptive data divided by the number of major
co‐morbidities are displayed in Table 1. Multi‐morbid patients
tended to be older and were more likely to be male. They
were more symptomatic, as evidenced by a higher proportion
with NYHA class III/IV symptoms despite higher LVEF and
lower LVEDd. Serum haemoglobin and albumin were also
lower in multi‐morbid patients.
Utilization of disease‐modifying agents
Overall, patients with multi‐morbidity were prescribed
lower equivalent doses of beta‐adrenoceptor antagonists
and ACEi and were less likely to be prescribed the maximum
licensed doses (Table 1). This was particularly evident in pa-
tients with COPD who were prescribed lower doses of
beta‐adrenoceptor antagonist, and those with CKD IV/V
who received lower doses of ACEi (Table 2). The presence
of any co‐morbidity was associated with a higher furosemide
equivalent dose of loop diuretic. In contrast, patients with
ischaemic aetiology of heart failure received similar doses
of beta‐adrenoceptor antagonist and ACEi as those with
non‐ischaemic cardiomyopathy, and patients with diabetes
mellitus were on average prescribed higher doses of both
classes of medications. There was no clear relationship be-
tween the number of co‐morbidities and the prescription of
MRA, although those with ischaemic aetiology of heart failure
and diabetes mellitus were more likely to be prescribed
these. The provision of CRT was similar in patients divided
by number of major co‐morbidities (Table 1). Patients with
an ischaemic aetiology were more likely to be implanted with
CRT or ICD, whilst patients with COPD were less likely to re-
ceive an ICD than were those without COPD (Table 2).
Mortality and modes of death
During an average follow‐up of 3.8 ± 1.6 years, a total of 737
(41.5%) patients died. Modes of death were available for 713
(97%), and 24 were unclassifiable owing to lack of informa-
tion. Of the classifiable deaths, progressive heart failure
caused 227 (32%) deaths, whereas 112 (16%) were sudden.
Non‐cardiovascular death occurred in 314 (44%) patients.
Mode of death and effect of multi‐morbidity
We observed a stepwise increase in the rate of all modes of
death in parallel with the number of major co‐morbidities
(Figure 1). When adjusted for age and sex, all major
co‐morbidities were associated with an increased risk of
all‐cause mortality (Figure 2). COPD was not associated with
an increased risk of death from progressive heart failure,
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although it was associated with a 2.5‐fold increased risk of
sudden death. CKD stage IV/V was associated with all‐cause
mortality and death from progressive heart failure, but the
association with sudden death was non‐significant. Diabetes
mellitus and ischaemic aetiology of heart failure increased
the risk of all modes of death.
In the multivariate analysis, major co‐morbidities were as-
sociated with all‐cause mortality, with the exception of isch-
aemic aetiology of heart failure (Table 3). However,
compared with all‐cause mortality and progressive heart fail-
ure deaths (Table 4), sudden deaths were not associated with
age, NYHA class III/IV symptoms, or LVEDd but were associ-
ated with lower LVEF (as a continuous variable) (Table 5).
Mode of death and disease‐modifying agents
In unadjusted survival analysis, higher doses of
beta‐adrenoceptor antagonist were associated with lower
rates of all‐cause, progressive heart failure, and sudden
deaths (Figure 3), whereas reductions in all‐cause mortality
with higher doses of ACEi were primarily driven by a reduc-
tion in progressive heart failure deaths and not sudden
deaths (Figure 4). Prescription of MRA was not associated
with lower rates of all‐cause mortality or sudden deaths;
however, there was a lower rate of progressive heart failure
deaths.
There were similar rates in the rates of sudden deaths
stratified by the dose of beta‐adrenoceptor antagonist in
those with and without specific co‐morbidities, which were
most evident in patients with ≥2 co‐morbidities (Figure 5).
When adjusted for age and sex, there was a relative reduc-
tion in sudden death of 9% per milligram bisoprolol equiva-
lent dose of beta‐adrenoceptor antagonist (P ¼ 0.001),
which was 11% (P ¼ 0.023) in patients with ≥2
co‐morbidities and 8% (P ¼ 0.071) in patients with <2 co‐
morbidities, with the exception of diabetes mellitus, which
was associated with a relative reduction in sudden death of
14% per milligram (P ¼ 0.005) compared with 7%
(P ¼ 0.084) in those without diabetes. In the multivariate
analysis, dosing of either class of medication was not associ-
ated with all‐cause mortality or non‐cardiovascular deaths
Table 1 Baseline characteristics of patients with 0, 1, 2, or ≥3 major co‐morbidities
All patients (n ¼ 1789) 0 (n ¼ 472) 1 (n ¼ 763) 2 (n ¼ 446) ≥3 (n ¼ 108) P‐value
Demographics
Age (years) 69.6 ± 12.5 64.4 ± 14.9 70.6 ± 12.0 72.9 ± 9.4 72.7 ± 8.3 <0.001
Male sex [n (%)] 1307 (73) 310 (66) 578 (76) 342 (77) 77 (71) <0.001
Major co‐morbidities
Ischaemic aetiology [n (%)] 1061 (59) 0 (0) 537 (70) 417 (94) 107 (99) <0.001
Diabetes mellitus [n (%)] 503 (28) 0 (0) 121 (16) 283 (63) 99 (92) <0.001
COPD [n (%)] 283 (16) 0 (0) 77 (10) 135 (30) 71 (66) <0.001
Observations
NYHA class III/IV [n (%)] 550 (31) 92 (20) 238 (31) 166 (37) 54 (50) <0.001
SBP (mmHg) 122.4 ± 21.6 122.4 ± 22.2 122.1 ± 20.9 121.4 ± 21.6 129.2 ± 23.1 0.02
DBP (mmHg) 71.5 ± 11.4 73.2 ± 11.9 71.3 ± 10.8 70.2 ± 11.5 70.1 ± 12.1 0.002
Heart rate (b.p.m.) 75.3 ± 17.9 79.2 ± 18.8 73.8 ± 18.0 74.1 ± 16.6 73.3 ± 15.0 <0.001
Echocardiogram
LVEDd (mm) 57.2 ± 8.9 58.5 ± 9.1 57.0 ± 8.8 56.4 ± 8.8 55.8 ± 8.6 0.001
LVEF (%) 32.0 ± 9.5 30.6 ± 10.0 32.3 ± 9.3 32.6 ± 9.1 33.7 ± 9.0 0.001
PASP (mmHg) 37.0 ± 13.6 34.6 ± 12.7 37.4 ± 13.1 37.0 ± 13.0 44.4 ± 19.6 0.002
RWMA [n (%)] 689 (39) 92 (34) 324 (72) 220 (86) 53 (83) <0.001
Blood tests
Hb (g/L) 13.5 ± 1.8 14.1 ± 1.6 13.4 ± 1.7 13.1 ± 1.8 12.4 ± 1.8 <0.001
eGFR (mL/min/1.73 m2) 57.7 ± 19.7 65.4 ± 16.1 58.6 ± 18.3 52.3 ± 20.5 40.9 ± 22.8 <0.001
Albumin (g/L) 42.9 ± 3.6 43.4 ± 3.4 43.0 ± 3.7 42.5 ± 3.4 42.4 ± 3.6 <0.001
Device therapy
ICD/CRT‐D [n (%)] 209 (12) 23 (5) 117 (15) 62 (14) 7 (7) <0.001
CRT‐P [n (%)] 452 (25) 103 (22) 206 (27) 118 (27) 25 (23) 0.19
Medications
Bisoprolol dose (mg) 3.9 ± 3.4 4.0 ± 3.3 3.9 ± 3.4 3.9 ± 3.4 3.3 ± 3.0 0.26
Maximum bisoprolol dose [n (%)] 271 (15) 71 (15) 122 (16) 66 (15) 12 (11) 0.61
Ramipril dose (mg) 4.9 ± 3.5 4.8 ± 3.4 5.1 ± 3.6 5.0 ± 3.6 3.9 ± 3.4 0.009
Maximum ramipril dose [n (%)] 492 (28) 114 (24) 229 (30) 130 (29) 19 (18) 0.012
Furosemide dose (mg) 51.3 ± 49.6 41.6 ± 46.1 45.1 ± 43.1 64.7 ± 54.3 82.6 ± 62.3 <0.001
MRA [n (%)] 684 (38) 161 (34) 287 (38) 196 (44) 40 (37) 0.021
Continuous variables are expressed as mean ± standard deviation; discrete variables are presented as number and percentages in paren-
theses. Comparisons across groups by ANOVA or χ2 for continuous and discrete variables, respectively.
CRT, cardiac resynchronization therapy; DBP, diastolic blood pressure; DCM, dilated cardiomyopathy; ECG, electrocardiogram; eGFR, es-
timated glomerular filtration rate; Hb, haemoglobin; ICD, implantable cardioverter defibrillator; LVEDd, left ventricular end‐diastolic di-
mension; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; PASP,
pulmonary artery systolic pressure; RWMA, regional wall motion; SBP, systolic blood pressure.
Bold emphasis is for P values which are statistically significant (<0.05).
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(Table 3); however, the association between dose of ACEi
and progressive heart failure death (Table 4) and of
beta‐adrenoceptor antagonist and sudden death was statisti-
cally significant (Table 5).
Discussion
In this analysis, we have reported the real‐world provision of
disease‐modifying agents in patients with HFrEF attending
specialist heart failure clinics in the UK. The novel findings
are that multi‐morbidity confers an additional risk of
all‐cause mortality, particularly due to sudden death, despite
the competing risk of non‐cardiovascular death for these pa-
tients. A diagnosis of COPD or diabetes mellitus was associ-
ated with >2.5‐fold and 1.5‐fold increased risk, even when
corrected for age, ischaemic aetiology of heart failure, and
degree of LV impairment. Patients with multi‐morbidity, es-
pecially COPD, were on average prescribed lower doses of
beta‐adrenoceptor antagonist and less likely to be implanted
Table 2 Baseline characteristics of patients with specific co‐morbidities
Ischaemic heart
failure
(n ¼ 1061)
Non‐ischaemic
cardiomyopathy
(n ¼ 728)
Diabetes
mellitus
(n ¼ 503)
No diabetes
mellitus
(n ¼ 1286) COPD (n ¼ 283)
No COPD
(n ¼ 1506)
CKD IV/V
(n ¼ 140)
No CKD
(n ¼ 1649)
Demographics
Age (years) 72.2 ± 10.3** 65.9 ± 14.4 70.2 ± 10.7 69.4 ± 13.2 73.2 ± 8.5** 69.0 ± 13.0 74.1 ± 11.8** 69.3 ± 12/5
Male sex [n
(%)]
832 (78)** 475 (65) 383 (76) 924 (72) 195 (69) 1112 (74) 85 (61)** 1222 (74)
Observations
NYHA class
III/IV [n (%)]
SBP (mmHg) 121.9 ± 21.6 123.2 ± 21.7 125.0 ± 21.0**121.5 ± 21.8122.9 ± 22.5 122.4 ± 21.5124.1 ± 23.4 122.3 ± 21.5
DBP (mmHg) 70.5 ± 11.1** 72.9 ± 11.7 71.0 ± 11.2 71.7 ± 11.5 71.3 ± 12.0 71.5 ± 11.3 68.9 ± 11.8* 71.7 ± 11.4
Heart rate
(b.p.m.)
71.9 ± 16.2** 80.3 ± 19.1 75.3 ± 17.2 75.3 ± 18.1 79.2 ± 17.4** 74.6 ± 17.9 73.0 ± 18.0 75.5 ± 17.9
Echocardiogram
LVEDd (mm) 56.9 ± 8.8 57.6 ± 9.1 56.3 ± 8.8* 57.5 ± 9.0 55.9 ± 8.7* 57.4 ± 8.9 55.3 ± 9.0* 57.3 ± 8.9
LVEF (%) 32.5 ± 9.1* 31.2 ± 10.0 33.1 ± 9.1** 31.5 ± 9.6 32.1 ± 9.6 31.9 ± 9.5 33.1 ± 9.2 31.9 ± 9.5
PASP
(mmHg)
37.0 ± 14.0 36.9 ± 13.1 40.8 ± 15.1** 35.8 ± 12.9 38.0 ± 13.8 36.8 ± 13.6 43.4 ± 16.8** 36.4 ± 13.1
RWMA [n
(%)]
564 (86)** 125 (33) 193 (72)* 496 (64) 112 (70) 577 (66) 57 (74) 632 (66)
Blood tests
Hb (g/L) 13.3 ± 1.7** 13.7 ± 1.8 13.0 ± 1.8** 13.6 ± 1.7 13.4 ± 1.8 13.5 ± 1.8 11.8 ± 1.7** 13.6 ± 1.7
eGFR (mL/
min/1.73 m2)
54.6 ± 19.3** 62.4 ± 19.3 54.4 ± 20.7** 59.1 ± 19.1 58.1 ± 20.1 57.7 ± 19.6 22.3 ± 6.7** 60.8 ± 17.3
Albumin (g/
L)
42.8 ± 3.5 43.0 ± 3.7 42.8 ± 3.4 43.0 ± 3.6 42.4 ± 3.5** 43.0 ± 3.6 40.9 ± 4.1** 43.1 ± 3.5
Device therapy
ICD/CRT‐D [n
(%)]
175 (17)** 34 (5) 58 (12) 151 (12) 19 (7)** 190 (13) 10 (7) 199 (12)
CRT‐P [n (%)] 295 (28)* 157 (22) 125 (25) 327 (25) 62 (22) 390 (26) 36 (26) 416 (25)
Medications
Bisoprolol
equivalent
dose (mg)
3.9 ± 3.4 3.8 ± 3.4 4.2 ± 3.5* 3.7 ± 3.3 2.7 ± 3.0** 4.1 ± 3.4 3.6 ± 3.0 3.9 ± 3.4
Maximum
bisoprolol
dose [n (%)]
161 (15) 110 (15) 92 (18)* 179 (14) 20 (7)** 251 (17) 17 (12) 254 (15)
Ramipril
equivalent
dose (mg)
5.0 ± 3.6 4.9 ± 3.5 5.3 ± 3.7** 4.8 ± 3.5 4.5 ± 3.3* 5.0 ± 3.6 3.1 ± 3.2** 5.1 ± 3.5
Maximum
ramipril dose
[n (%)]
301 (28) 191 (26) 168 (33)** 324 (25) 60 (21)* 432 (29) 18 (13)** 474 (29)
Furosemide
equivalent
dose (mg)
53.8 ± 50.5* 47.7 ± 48.1 68.3 ± 55.9** 44.7 ± 45.3 58.2 ± 50.0* 50.0 ± 49.5 83.0 ± 62.1** 48.6 ± 47.5
MRA [n (%)] 436 (41)** 248 (34) 216 (43)* 468 (36) 101 (36) 583 (39) 48 (34) 636 (39)
Continuous variables are presented as mean ± standard deviation; discrete variables as number (percentage).
CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; DM, diabetes mellitus;
HF, heart failure; ICD, implantable cardioverter defibrillator.
*P < 0.05.
**P < 0.005.
Medication, mortality, and multi‐morbidity 5
ESC Heart Failure ; :
DOI: 10.1002/ehf2.12978
with ICDs. Higher doses of beta‐adrenoceptor antagonists
were associated with lower rates of sudden death, especially
evident in multi‐morbid patients, and there was a modest re-
duction in sudden death associated with ICD implantation.
Cumulatively, these data suggest that there might be a
missed opportunity to optimize disease‐modifying agents to
reduce the risk of sudden death in patients with HFrEF and
that patients with co‐morbidity might have the most to gain
from targeted dose optimization and device implantation.
Multi‐morbidity and the risk of sudden death in
heart failure with reduced ejection fraction
To date, few studies have reported the association between
multi‐morbidity and modes of death in HFrEF. In one retro-
spective analysis of an historic cohort including 824 patients,
multi‐morbidity was found to reduce the risk of sudden
death, attributed to the competing risk of non‐sudden
death.22 However, this study was limited by a low rate of sud-
den deaths (n ¼ 30), and patients were enrolled between
1998 and 2004, predating the increased penetration of con-
temporaneous medical therapy in HFrEF. This study also de-
fined multi‐morbidity using the Charlson co‐morbidity index,
which is heavily weighted towards advanced age. In our anal-
ysis, we have shown that age is not associated with an in-
creased risk of sudden death in HFrEF but is a major driver
of all‐cause mortality. Our dataset included 112 sudden death
events allowing the description of a stepwise increase in the
relative risk of sudden death in those with multiple major
co‐morbidities. Our data do not describe the effects of other
co‐morbidities, such as hypertension and atrial fibrillation on
modes of death; however, in our patients, there were no sig-
nificant differences in all‐cause mortality in patients with and
without these.23
Sudden deaths in patients with HFrEF are often caused by
ventricular tachyarrhythmias, one driver of which could be
acute coronary syndromes.24 Our findings might therefore
be partially explained by a greater burden of coronary artery
disease in patients with diabetes mellitus, COPD, and CKD.
However, we found that diabetes mellitus and COPD were in-
dependent risk factors for sudden death even after correction
for ischaemic aetiology of heart failure. Furthermore, clinical
trials of statins,25,26 aspirin, and anticoagulants,27,28 which re-
duce the incidence of acute coronary syndromes, do not re-
duce sudden death in HFrEF. Alternative contributors could
include myocardial fibrosis, which is more common in people
with diabetes mellitus, is found in patients with and without
ischaemic heart disease,29 and is a substrate for ventricular
tachyarrhythmias. Diabetes mellitus increased the risk of sud-
den death, despite higher doses of beta‐adrenoceptor antag-
onists and ACEi in this cohort and a similar ICD implantation
rate as non‐diabetic patients. COPD is associated with sudden
death and an increased risk of ventricular tachyarrhythmias30
in patients with and without HFrEF, related to the duration of
disease and the frequency of exacerbations31 possibly due to
autonomic dysregulation,32 higher resting heart rates,33 hyp-
oxia, and chronic systemic inflammation.31
The role of medical and device therapy in
preventing sudden death
Contemporary medical and device therapies have resulted
in dramatic reductions in sudden deaths in patients with
HFrEF between therapeutic eras.4 Medical therapy including
ACEi,34,35 beta‐adrenoceptor antagonists,2,3 and MRA36,37
synergistically reduce all‐cause mortality in HFrEF; and in
our patients, we observed a clear stepwise reduction in the
risk of all‐cause mortality in patients receiving the highest
doses of ACEi and beta‐adrenoceptor antagonists. The associ-
ation between higher doses of ACEi and all‐cause mortality
was primarily due to lower rates of progressive heart failure,
whereas beta‐adrenoceptor antagonists were associated with
lower rates of both progressive heart failure and sudden
deaths. The prescription of MRA was associated with lower
rates of progressive heart failure deaths but not all‐cause
mortality or sudden deaths.
Multi‐morbid patients were on average prescribed
lower doses of disease‐modifying pharmacotherapies than
were patients without co‐morbidities; in particular, we ob-
served lower dosing of ACEi in those with CKD and of
beta‐adrenoceptor antagonists in those with COPD. Although
key co‐morbidities were associated with lower dosage of
pharmacological therapy, we lack qualitative data on the
reasons for failure to up‐titrate for patients in whom blood
pressure and heart rate allowed. The prescription of
beta‐adrenoceptor antagonists for patients with COPD is typ-
ically well tolerated with minimal changes in lung function
Figure 1 Bar chart to show the modes of death in patients with 0, 1, 2,
and ≥3 major co‐morbidities. Patients with multi‐morbidity are at in-
creased risk of all‐cause, non‐cardiovascular, progressive heart failure
and sudden death.
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and improvements in survival even in those with the most se-
vere disease.38 However, the use of non‐selective agents has
been shown to reduce persistence time and to increase
discontinuation rates and the risk of heart failure hospitaliza-
tion, and so therapies should be tailored for individual
patients.39 In our patients, those with diabetes mellitus were
prescribed, on average, higher doses of beta‐adrenoceptor
antagonists. Historically, there have been concerns about
prescribing these medications to those receiving insulin or
sulfonylureas owing to perceived risks of masking symptoms
of hypoglycaemia or prolonging these episodes.40 However,
in clinical trials, rates of hypoglycaemia are not different,
and the theoretical risks are far outweighed by the
established benefits.3
In our patients, more severely impaired LV function was
strongly associated with an increased risk of sudden death.
Treatments such as CRT41,42 and angiotensin‐receptor
neprilysin inhibitor (ARNI) reduce the risk of sudden death,
primarily by their ability to promote reverse ventricular re-
modelling, and beta‐adrenoceptor antagonists might also re-
duce the risk of sudden mechanical failure by facilitating
dose‐related improvement in LV function and are associated
Figure 2 Forrest plot showing the hazard of all‐cause, progressive heart failure, and sudden death in patients with major co‐morbidities. Any co‐mor-
bidities, but particularly COPD and diabetes mellitus, increase the risk of sudden death.
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with similar improvements in survival whether target dose or
heart rate is achieved.43,44 However, beta‐adrenoceptor an-
tagonists are also protective against ventricular tachyarrhyth-
mias and surges in the autonomic nervous system, which can
precipitate electrical and mechanical instability and in part re-
duce the risk of sudden death, improving survival in those
prescribed the highest doses.
Patients with COPD are around twice as likely to receive
appropriate therapies when implanted with ICDs than are
those without,45 yet patients with COPD in our cohort were
less likely to be implanted, the implications being that implan-
tation should not be avoided in multi‐morbid patients
who are at the highest risk of sudden death. Whilst ICDs
have an established role in the prevention of sudden cardiac
death in both ischaemic heart failure and non‐ischaemic
cardiomyopathies,46–48 in clinical trials, ~50–70% of sudden
deaths are not prevented by implantation.6 This is confirmed
in the present study where ICDs were only modestly protec-
tive against sudden death contrasting with the strong associ-
ations with beta‐adrenoceptor antagonists. Hence, other
mechanisms of sudden death must be at play in HFrEF, which
could include rapidly deteriorating pump function.
Strengths and limitations
This is an analysis of data from a carefully characterized co-
hort of patients with HFrEF, with long‐term follow‐up. Our
study reports the provision of medical and device therapy in
a real‐world population, with doses achieved similar to other
observational studies with similar proportions with major co‐
morbidities, albeit a lower proportion with COPD.49,50 The ex-
clusion of patients with LVEF > 45% means that our findings
are not generalizable to patients with heart failure with pre-
served ejection fraction but are applicable to many patients
with heart failure and mid‐range ejection fraction. The study
was a retrospective analysis of modes of death, and misclas-
sification is a possibility, although this is unlikely to be biased
to a particular mode. We did not analyse the effect of other
co‐morbidities on modes of death or the effects of
non‐cardiovascular medications; however, we present an
analysis of the four most prevalent major co‐morbidities in
the patient population studied.10 The study predated the
availability of ARNI, which are associated with additional re-
ductions in progressive heart failure and sudden deaths.
Table 3 Multivariate regression analysis of all‐cause mortality in all
patients
Hazard
ratio 95% CI P‐value
Age (per year) 1.04 1.03–1.05 <0.001
Male sex 1.75 1.49–2.06 <0.001
Ischaemic heart failure 1.09 0.94–1.26 0.27
Diabetes mellitus 1.32 1.14–1.53 <0.001
COPD 1.65 1.40–1.94 <0.001
NYHA class III/IV 1.26 1.10–1.45 0.001
LVEDd (per mm) 1.00 0.99–1.01 0.73
LVEF (per %) 0.99 0.98–0.99 <0.001
Hb (per g/dL) 0.88 0.84–0.92 <0.001
eGFR (per mL/min/1.73 m2) 0.99 0.99–1.00 0.001
Albumin (per g/L) 0.96 0.94–0.97 <0.001
Bisoprolol equivalent dose
(per mg)
1.00 0.98–1.02 0.73
Ramipril equivalent dose
(per mg)
0.98 0.96–1.00 0.066
Furosemide equivalent dose
(per mg)
1.00 1.00–1.00 <0.001
CI, confidence interval; COPD, chronic obstructive pulmonary dis-
ease; DCM, dilated cardiomyopathy; Hb, haemoglobin; LVEDd, left
ventricular diameter in diastole; NYHA, New York Heart Associa-
tion; PASP, pulmonary artery systolic pressure.
Bold emphasis is for P values which are statistically significant
(<0.05).
Table 4 Multivariate regression analysis of progressive heart fail-
ure deaths in all patients
Hazard ratio 95% CI P‐value
Age (per year) 1.05 1.03–1.06 <0.001
Male sex 1.78 1.25–2.54 0.001
Ischaemic heart failure 1.45 1.04–2.01 0.028
Diabetes mellitus 1.32 0.98–1.79 0.072
NYHA class III/IV 1.41 1.06–1.87 0.019
LVEDd (per mm) 1.03 1.01–1.05 0.004
LVEF (per %) 0.98 0.96–0.99 0.007
Hb (per g/dL) 0.88 0.80–0.96 0.005
eGFR (per mL/min/1.73 m2) 0.99 0.98–1.00 0.002
Albumin (per g/L) 0.96 0.93–1.00 0.045
Bisoprolol equivalent dose
(per mg)
0.96 0.92–1.01 0.11
Ramipril equivalent dose
(per mg)
0.93 0.89–0.97 0.001
Furosemide equivalent dose
(per mg)
1.01 1.00–1.01 <0.001
CI, confidence interval; COPD, chronic obstructive pulmonary dis-
ease; DCM, dilated cardiomyopathy; Hb, haemoglobin; LVEDd, left
ventricular diameter in diastole; NYHA, New York Heart Associa-
tion; PASP, pulmonary artery systolic pressure.
Bold emphasis is for P values which are statistically significant
(<0.05).
Table 5 Multivariate regression analysis of sudden death in all
patients
Hazard ratio 95% CI P‐value
Age (per year) 0.99 0.97–1.01 0.33
Male sex 1.83 1.11–3.00 0.017
Ischaemic heart failure 1.48 0.95–2.29 0.08
Diabetes mellitus 1.59 1.06–2.38 0.024
COPD 2.53 1.64–3.90 <0.001
LVEF (per %) 0.97 0.95–0.99 0.005
eGFR (per mL/min/1.73 m2) 0.99 0.98–1.00 0.013
Bisoprolol equivalent dose
(per mg)
0.92 0.86–0.98 0.009
CI, confidence interval; COPD, chronic obstructive pulmonary dis-
ease; eGFR, estimated glomerular filtration rate; LVEF, left ventricu-
lar ejection fraction.
Bold emphasis is for P values which are statistically significant
(<0.05).
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Figure 3 Kaplan–Meier plots of all‐cause, progressive heart failure, and sudden death stratified by bisoprolol equivalent dose of beta‐adrenoceptor
antagonist. Escalating doses of beta‐adrenoceptor antagonists are protective against all‐cause, progressive heart failure, and sudden death.
Figure 4 Kaplan–Meier plots of all‐cause, progressive heart failure, and sudden death stratified by ramipril equivalent dose of angiotensin‐converting
enzyme‐inhibitors (ACEi). Escalating dose of ACEi is protective against all‐cause and progressive heart failure death, but not sudden death.
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Conclusions
This study is the first to report real‐world provision of
disease‐modifying agents and demonstrate an increased
risk of sudden death in multi‐morbid patients with HFrEF.
Higher doses of beta‐adrenoceptor antagonist are associ-
ated with greater protection from sudden death, most evi-
dent in multi‐morbid patients. Patients with COPD who
appear to be at the highest risk of sudden death are pre-
scribed the lowest doses of beta‐adrenoceptor antagonists
and less likely to be implanted with ICDs. This might repre-
sent a missed opportunity to optimize safe and proven
therapies, and additional efforts are needed where
co‐morbidities exist.
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